Table 1 Clinical characteristics for the three groups of patients included in the study.
Sex | Age | Evolution time (months) | Other allergens | RCSS | Medication score | Intradermal test to DP (mm2) | Concentration DP at positive nasal provocation test | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Basal | 12 month | p | Basal | 12 month | p | Basal | 12 month | p | Basal | 12 month | p | |||||
RP | 35.7% | 28 | 36 | 83.3% | 2,17 | 1,55 | 0.002 | 0,54 | 0,25 | 0.050 | 149 | 100 | 0.084 | 0,04 | 0,04 | 0.473 |
n = 28 | Females | (21–31) | (24–120) | (1,35–2,92) | (1,32–2,85) | (0,07–1,2) | (0,07–1,21) | (90–168) | (88,5–148) | (0,04–4) | (0,04–0,4) | |||||
NRP | 66.7% | 33 | 180 | 66.6% | 3,85 | 8,32 | 0.063 | 0,25 | 0,67 | 0.458 | 172 | 109,5 | 0.157 | 0,04 | 0,04 | 0.157 |
n = 6 | Females | (30–33) | (180–240) | (1,58–4,95) | (6,52–9,43) | (0,12–0,42) | (0,57–0,88) | (168–176) | (99–120) | (0,04–0,4) | (0,04–0,04) | |||||
CG | 40% | 19 | 60 | 60% | 4,745 | 5,53 | 0.122 | 0,07 | 0,46 | 0.458 | 132 | 143 | 0.916 | 0,4 | 0,04 | 0.008 |
n = 10 | Females | (19–31) | (24–120) | (1,46–5,89) | (0,92–7,6) | (0–0,41) | (0–2,03) | (118,25–189) | (83,5–191,25) | (0,04–0,4) | (0,04–0,04) | |||||
